Overview

An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.
Phase:
Phase 2
Details
Lead Sponsor:
Anavex Life Sciences Corp.